CXCL1 and melanoma: Spranger and colleagues identified a pathway in human melanoma, in which β-catenin produced by tumor cells suppresses the recruitment of CD103+ dendritic cells (DCs) by downregulating CCL3, CCL4, CXCL1, and CXCL2.